JP2013543862A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543862A5
JP2013543862A5 JP2013538324A JP2013538324A JP2013543862A5 JP 2013543862 A5 JP2013543862 A5 JP 2013543862A5 JP 2013538324 A JP2013538324 A JP 2013538324A JP 2013538324 A JP2013538324 A JP 2013538324A JP 2013543862 A5 JP2013543862 A5 JP 2013543862A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
composition according
agents
pkc
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013538324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543862A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2011/000866 external-priority patent/WO2012063237A2/en
Publication of JP2013543862A publication Critical patent/JP2013543862A/ja
Publication of JP2013543862A5 publication Critical patent/JP2013543862A5/ja
Pending legal-status Critical Current

Links

JP2013538324A 2010-11-08 2011-11-08 眼科用緩衝組成物およびその使用方法 Pending JP2013543862A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41146410P 2010-11-08 2010-11-08
US41146610P 2010-11-08 2010-11-08
US61/411,466 2010-11-08
US61/411,464 2010-11-08
PCT/IL2011/000866 WO2012063237A2 (en) 2010-11-08 2011-11-08 Buffered ophthalmic compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2013543862A JP2013543862A (ja) 2013-12-09
JP2013543862A5 true JP2013543862A5 (cg-RX-API-DMAC7.html) 2014-12-25

Family

ID=46051349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538324A Pending JP2013543862A (ja) 2010-11-08 2011-11-08 眼科用緩衝組成物およびその使用方法

Country Status (8)

Country Link
US (2) US20120264681A1 (cg-RX-API-DMAC7.html)
EP (2) EP2944319A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013543862A (cg-RX-API-DMAC7.html)
CN (2) CN104758921A (cg-RX-API-DMAC7.html)
AU (1) AU2011327785A1 (cg-RX-API-DMAC7.html)
CA (1) CA2812164A1 (cg-RX-API-DMAC7.html)
RU (1) RU2013117209A (cg-RX-API-DMAC7.html)
WO (1) WO2012063237A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
CN104758921A (zh) 2010-11-08 2015-07-08 希尔洛有限公司 缓冲的眼用组合物以及使用其的方法
US20130296250A1 (en) * 2011-01-11 2013-11-07 Healor Ltd. Method for treatment of psoriasis
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
AU2014259948B2 (en) * 2013-04-30 2019-04-18 University Of Southern California Accelerated healing of eye injuries by angiotensin peptides
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
EP3210614A4 (en) 2014-10-22 2018-06-13 G-Treebnt Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
EP3011959A1 (en) 2014-10-23 2016-04-27 Santen SAS Quaternary ammonium compound for use as an inhibitor of protein kinase C alpha
CN104940904A (zh) * 2015-05-27 2015-09-30 北京爱特普科技有限公司 一种腔体粘膜微生态调节剂及其制备方法
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR20170021667A (ko) * 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
WO2017055924A2 (en) 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
WO2017178892A2 (en) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
JP6943707B2 (ja) * 2016-08-23 2021-10-06 積水化学工業株式会社 水溶性樹脂組成物及び水溶性樹脂フィルム
WO2018045091A1 (en) * 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
US10918699B2 (en) 2017-03-22 2021-02-16 Michael C. Struck Therapeutic treatment for neurotrophic keratopathy
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
MX2020004251A (es) 2017-10-19 2021-05-27 Mona E Buice Composición tópica para cicatrización mejorada de heridas abiertas.
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
JP2020075918A (ja) * 2018-11-02 2020-05-21 千寿製薬株式会社 角膜上皮創傷治癒促進用の眼科用組成物
AU2020224106A1 (en) * 2019-02-20 2021-09-09 Eleos Pharmaceuticals, Llc Topical composition for improved healing of ocular ailments
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
CN111610334A (zh) * 2020-05-18 2020-09-01 山东省肿瘤防治研究院(山东省肿瘤医院) 一种基于细胞大小过滤识别肿瘤患者外周血循环肿瘤细胞的方法
CN118340775A (zh) * 2023-01-09 2024-07-16 维眸生物科技(浙江)有限公司 一种含vvn539的眼用组合物及其用途
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549747A (en) 1968-02-20 1970-12-22 Flow Pharma Inc Contact lens wetting solution and method of using same
US3947573A (en) 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3856919A (en) 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3767788A (en) 1970-06-08 1973-10-23 Burton Parsons Chemicals Inc Ophthalmic solution
US3767789A (en) 1971-06-21 1973-10-23 Burton Parsons & Co Inc Method of providing a synthetic mucus in vivo
US3907985A (en) 1973-07-27 1975-09-23 Burton Parsons And Company Inc Polystyrene sulfonate containing opthalmic solutions
US3987163A (en) 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US4029817A (en) 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US3920810A (en) 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4120949A (en) 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JP3059092B2 (ja) * 1995-11-15 2000-07-04 田辺製薬株式会社 ドライアイおよびドライアイを原因とする疾患の予防・治療剤
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
JP4790609B2 (ja) * 2003-07-15 2011-10-12 バーイラン ユニバーシティー 創傷治癒のための方法及び薬剤組成物
ES2375565T3 (es) * 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
ITMI20052036A1 (it) * 2005-10-26 2007-04-27 Professional Dietetics Srl Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
US20080292726A1 (en) * 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
US20090124553A1 (en) * 2007-05-04 2009-05-14 Mochly-Rosen Daria D Suppression of inflammation associated with transplantation using an epsilon PKC inhibitor
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
US20130012447A1 (en) * 2007-08-27 2013-01-10 Eiketsu Sho Protein kinase c-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
JP5421910B2 (ja) * 2008-06-19 2014-02-19 学校法人近畿大学 ペプチド誘導体およびそれを含む涙液分泌促進組成物
US20110223177A1 (en) * 2008-09-09 2011-09-15 University Of East Anglia Treatment of fibrotic eye disorders
EP2599494A1 (en) * 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
CN104758921A (zh) 2010-11-08 2015-07-08 希尔洛有限公司 缓冲的眼用组合物以及使用其的方法

Similar Documents

Publication Publication Date Title
JP4516844B2 (ja) 創傷の処置におけるラクトフェリン
US7557087B2 (en) Compositions and methods for treating diseases
RU2013117209A (ru) Буферные глазные композиции и способы их применения
ES2335437T3 (es) Composiciones farmaceuticas oftalmicas a base de aminoacidos y de hialuronato de sodio.
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
US20110275688A1 (en) Ketorolac compositions for corneal wound healing
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
US20250000790A1 (en) Ketorolac compositions for corneal wound healing
ES2818824T3 (es) Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
RU2017118405A (ru) Новое лечение роговицы с применением ламинина
RU2008140117A (ru) МОНОМЕР TGF-β И ЕГО ПРИМЕНЕНИЕ
KR101521278B1 (ko) 펩티드 유도체 및 이를 포함하는 누액 분비 촉진 조성물
AU2023200154A1 (en) Dosing regimens for treating hypoxia-associated tissue damage
JP2005272445A (ja) 涙液分泌促進ペプチドおよびその組成物
RU2004105844A (ru) Новое применение 2-[5-(4-фторфенил)-3-пиридилметиламинометил]-хромана и его физиологически приемлемых солей
EP4100044A1 (en) Compositions comprising amelogenin and uses thereof
CN106488773B (zh) Apc类似物用于创伤愈合的用途
TWI758272B (zh) 用於治療傷口之清創組合物
EA201490173A1 (ru) Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции
JP2011221464A (ja) コンタクトレンズ用眼科組成物
Tchalakov et al. Treatment of Recurrent Respiratory Papilomatosis Type II on the Larynx
RU2009107917A (ru) Аминоизохинолиновый ингибитор тромбина с улучшенной биодоступностью
RU2013153733A (ru) Композиция для лечения остеоартрита на основе модифицированной гиалуроновой кислоты или ее соли (варианты) и способ лечения остеоартрита
WO2014071005A1 (en) Methods and compositions using neuroprotective steroids and thrombolytic agents